NEW YORK (GenomeWeb News) – Seegene and Shimadzu jointly announced today that they will collaborate on developing molecular diagnostics tests that will run on Shimadzu’s MultiNA high-speed electrophoresis system.
Seegene makes the Seeplex family of PCR-based, multi-pathogen tests. The Rockville, Md.-based firm makes screening tests for STDs, respiratory viruses, human papillomavirus, sepsis, and pneumonia, it said.
Shimadzu’s MultiNA platform, which is indicated for research use only, uses microchip technology to perform fully automated, high-speed electrophoresis separation, fluorescence detection, and high-sensitivity analysis.
Jong-Yoon Chun, founder and CEO of Seegene, said that Shimadzu’s MultiNA platform is “a perfect match for the Seeplex family of multi-pathogen tests.”